LFB-SA
Key events in 2015 :
- Launched a new generation plant financed by a €230 million capital increase, fully underwritten by the French State, currently the sole shareholder of LFB.
- Two new products registered in Europe
- Significant investment in R&D with €81.3 million* owing to several products currently in phase III trials
- Gross margin in decline as compared to 2014 due to the production of commercial batches for phase III products
- Turnover of €502.4 million, stable in comparison to 2014
Christian Béchon, Chief Executive Officer of L.F.B S.A. declared:
"In
2015, the key milestones have been successfully achieved. It has been a
historic and productive year for the future of LFB."
An unprecedented increase in capital in order to finance the group's
development
As part of the group's strategic development, LFB's
shareholder (the French State) decided in October to underwrite an
increase in LFB's share capital by €230 million. The share capital of
the company now stands at €280 million. To meet the financing needs of
LFB's development project, on 5 January 2016 LFB issued a senior bond of
€124 million. These funds will enable the construction of a 'new
generation' plant in Arras. This flagship project, representing an
investment of approximately €300 million, will enable LFB to triple its
global production capacity in 2020 with facilities aimed at
manufacturing for the whole world.
LFB is also developing its sites
in Alès (Gard) and Charlton (USA), establishing bio-production
facilities for recombinant medicines in development.
|
Consolidated earnings in €M |
2015 | 2014 | Variation 2015/2014 | |||
|
Turnover |
502.4 |
501.9 |
0.1 % |
|||
|
Gross margin |
177.6 |
195.5 |
-9.2 % |
|||
|
Research & development |
(81.3) |
(65.9) |
||||
|
Commercial costs |
(51.0) |
(48.6) |
||||
|
General costs |
(50.3) |
(48.7) |
||||
|
Other charges and |
17.0 |
(7.1) |
||||
|
Operational earnings |
12.0 |
25.2 |
||||
|
as a % of turnover |
2.4 % |
5.0 % |
||||
|
Net earnings |
0.3 |
13 |
€90.5 million* before research tax credit
2015 turnover - growth in international sales
At €502.4
million, turnover is relatively stable as compared to 2014. For the
second successive year, the group's turnover exceeded €500 million, with
the international side business continuing to grow. Despite a 3.2 %
decline in turnover in France during 2015, international sales rose by
€12.1 million (+8.7%), reaching €152 million. This figure represents 30%
of consolidated turnover (28% in 2014).
Operational earnings decline in order to finance strategy
Research
and development costs are increasing rapidly (€81.3 million), owing to
the large number of phase III trials in progress. Various strategic
projects reached significant milestones. In 2015, two new LFB products,
a 10% immunoglobulin and a fibrinogen have been subject to a mutual
recognition in procedure in Europe with the Paul Ehrlich Institute as
the referral agency. Two other recombinant products are currently at the
end of phase III. At the same time, LFB is planning to manufacture
product batches for launch, which has had an impact on earnings. In
2015, the group posted encouraging operational income (€17 million),
notably owing to its holding in the bio-tech company TG Therapeutics
Inc. The positive operational earnings (€12.0 million) is down as
compared to that of 2014 (-13.2 million) due to a decline in gross
margins and increased development costs. Despite this unprecedented
effort, net earnings remain positive at €0.3 million.
About LFB Group
LFB is a
bio-pharmaceutical company that develops, manufactures, and markets
medicinal products from living systems for the treatment of serious and
often rare diseases in the fields of Immunology, Hemostasis, Perinatal,
and Intensive Care. Currently ranked 6th worldwide in the field of
plasma-derived medicinal products, LFB Group is also among the leading
European companies in the development and production of proteins and
innovative treatments derived from bio-technologies. It employs 2,111
staff worldwide.
http://www.groupe-lfb.fr
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005971/en/
Contact:
LFB SA
Sandrine Charrières, 01.69.82.72.80
Communication
Director
charrieres@lfb.fr
or
David
Loison, 01.69.82.70.20
Financial Affairs Director
loisond@lfb.fr
or
Havas
Worldwide
Jeanne Bariller, 06.15.51.49.40
jeanne.bariller@havasww.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom